With American Pharmacists Month (APhM) behind us, I wanted to take a moment to celebrate the spotlights that shined on our profession, focusing on our pharmacists, student pharmacists, pharmacy technicians, and the incredible work that they do. We saw APhM recognized across social media channels, state proclamations by governors, and even through an on-camera shout out at the TODAY Show on their plaza. This well-deserved recognition goes a long way in sharing with the world the value and importance of pharmacists and pharmacy personnel in all settings.

WASHINGTON, DC—The American Pharmacists Association announced today that its 2023–2024 class of executive residents and fellows has been selected.

A new survey from Wolters Kluwer Health reflects increasing trust in providers in non-traditional primary care settings.

FDA has approved buprenorphine extended-release injection (Brixadi—Braeburn) for the treatment of moderate to severe opioid use disorder (OUD). The drug is available as a weekly dose for patients who have started treatment with a single dose of a transmucosal buprenorphine product and as a monthly version for patients already being treated with buprenorphine.